Sareum Holdings plc (AIM:SAR)

Market Cap	20.71M
Revenue (ttm)	n/a
Net Income (ttm)	-4.44M
Shares Out	138.07M
EPS (ttm)	-0.04
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	38,154
Average Volume	237,964
Open	15.70
Previous Close	15.00
Day's Range	14.92 - 15.70
52-Week Range	9.50 - 29.00
Beta	-1.06
RSI	54.48
Earnings Date	Mar 20, 2026

About Sareum Holdings

Sareum Holdings plc, a clinical stage small molecule drug development company, engages in the discovery and development of therapeutic drugs for cancer and autoimmune diseases. The company’s lead product is SDC-1801, a TYK2/JAK1 inhibitor which has completed Phase 1 clinical trial for the treatment of autoimmune diseases. It also develops SDC-1802, a TYK2/JAK1 inhibitor, that is in preclinical stage for cancer and cancer-immunotherapy applications; and SRA737, a clinical-stage oral, selective Chk 1 inhibitor, which has completed Phase II clinic...

• Industry: Biotechnology
• Sector: Healthcare
• Founded: 2004
• Employees: 5
• Stock Exchange: London Stock Exchange AIM
• Ticker Symbol: SAR